Download Files:
Products Details
Product Description
– ADU-S100 (MIW815), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity[1].
Web ID
– HY-12885
Storage Temperature
– -20°C (Powder, protect from light)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H24N10O10P2S2
Citations
– Acta Crystallogr D Struct Biol. 2020 Sep 1;76(Pt 9):889-898. |Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12.|Cell Mol Gastroenterol Hepatol. 2021 Feb 3;S2352-345X(21)00024-2.|Environ Int. 2020 Oct;143:105949.|Eur J Med Chem. 2023 Feb 4;250:115184.|Front Immunol. 2021 Jul.|Front Immunol. 2023 Oct 13:14:1258691.|Immunology. 2022 Jul 20.|Inflamm Res. 2023 Jul 11.|J Immunother Cancer. 2019 Sep 18;7(1):252. |J Neuroinflammation. 2023 Apr 30;20(1):101.|Mol Cell Biochem. 2021 Feb;476(2):1015-1024.|Nat Commun. 2023 Mar 13;14(1):1390.|Nat Commun. 2023 Sep 18;14(1):5666.|Nat Nanotechnol. 2021 Sep 30.|Neuron. 2022 Nov 4;S0896-6273(22)00961-8.|Patent. US20200146975A1|Patent. US20210205468A1.|Patent. US20230062932A1.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2022 Jan.|University of Toronto. 2023 Jun.|Biomaterials. 2018 May;163:67-75. |bioRxiv. October 23, 2021.|Cancer Cell. 2020 Mar 16;37(3):289-307.e9. |Commun Biol. 2021 Apr 22;4(1):497.|Eur J Med Chem. 2022 Sep 28;243:114796.|Nat Commun. 2022 May 31;13(1):3022.|Nature. 2023 Apr;616(7958):806-813.|Patent. US20210322327A1.|Patent. US20220162199A1.|Patent. US20220395465A1.|PLoS One. 2020 Sep 10;15(9):e0237743.|University of Pittsburgh. School of Medicine. 2021 May 14.|Cell Death Dis. 2022 Jul 28;13(7):653.|Nat Commun. 2023 Oct 2;14(1):6132.
References
– [1]Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018-30.
CAS Number
– 1638241-89-0
Molecular Weight
– 690.54
Compound Purity
– 99.85
SMILES
– O[C@H]1[C@](O[P@](S)(OC[C@](O[C@](N2C3=NC=NC(N)=C3N=C2)([H])[C@@H]4O)([H])[C@@]4([H])O5)=O)([H])[C@@](N6C7=NC=NC(N)=C7N=C6)([H])O[C@]1([H])CO[P@]5(S)=O
Clinical Information
– Phase 1
Research Area
– Inflammation/Immunology; Cancer
Solubility
– H2O : 20 mg/mL (ultrasonic)
Target
– STING
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
